15 October 2015 - Belatacept (Nulojix) has been approved since June 2011 for use by adults after a kidney transplant. After a first early benefit assessment in April 2012, the German Institute for Quality and Efficiency in Health Care (IQWiG) now re-examined whether the drug offers an added benefit over the appropriate comparator therapy. This new assessment was conducted because a limitation of the corresponding decision by the Federal Joint Commission (G-BA) expired in July 2015.

For more details, go to: https://www.iqwig.de/en/press/press-releases/press-releases/belatacept-after-a-kidney-transplant-indication-of-considerable-added-benefit.6927.html